| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14737167.2014.861742 |
| P698 | PubMed publication ID | 24325566 |
| P2093 | author name string | Carlo A Marra | |
| Kam Shojania | |||
| Nicole W Tsao | |||
| P2860 | cites work | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis | Q21134808 |
| Environmental influences on risk for rheumatoid arthritis | Q24618377 | ||
| The Stanford Health Assessment Questionnaire: dimensions and practical applications | Q24806173 | ||
| 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 | ||
| Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study | Q42634784 | ||
| Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study | Q42674160 | ||
| Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 | ||
| Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period | Q44506234 | ||
| Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 | ||
| The burden of rheumatoid arthritis and access to treatment: health burden and costs | Q46256192 | ||
| Societal cost of rheumatoid arthritis patients in the US. | Q48956161 | ||
| Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. | Q51728611 | ||
| Not all "quality-adjusted life years" are equal. | Q51915240 | ||
| Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. | Q51916190 | ||
| Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 | ||
| 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q56506042 | ||
| Rheumatoid arthritis | Q57349151 | ||
| Now that we know what's BeSt, what is good value for the money? | Q57995474 | ||
| Biologic agents in rheumatoid arthritis: an update for managed care professionals | Q27023565 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes | Q33336433 | ||
| Abatacept for rheumatoid arthritis: a Cochrane systematic review | Q33524713 | ||
| Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice | Q33637603 | ||
| Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting | Q33726931 | ||
| Economic burden of rheumatoid arthritis: a systematic review | Q33831406 | ||
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation | Q33856555 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis | Q34401259 | ||
| Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. | Q34986307 | ||
| The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis | Q35094697 | ||
| Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain | Q35113679 | ||
| Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. | Q35590496 | ||
| Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial | Q35638718 | ||
| A review of the MHC genetics of rheumatoid arthritis. | Q35642056 | ||
| Modelling in the economic evaluation of health care: selecting the appropriate approach | Q35751780 | ||
| Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland | Q35952231 | ||
| Epidemiology of adult rheumatoid arthritis | Q36095154 | ||
| International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review | Q36100671 | ||
| Early environmental factors and rheumatoid arthritis | Q36347898 | ||
| Risk factors for the development of rheumatoid arthritis | Q36502903 | ||
| New cytokine targets in inflammatory rheumatic diseases | Q36596133 | ||
| Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study | Q36610390 | ||
| Cardiovascular co-morbidity in rheumatic diseases | Q36835851 | ||
| Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q36930704 | ||
| Evidence that cytokines play a role in rheumatoid arthritis | Q37316594 | ||
| New understanding and approaches to treatment in rheumatoid arthritis. | Q37702016 | ||
| The burden of illness of rheumatoid arthritis | Q37848120 | ||
| Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs | Q37932896 | ||
| The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis | Q38065449 | ||
| The widening mortality gap between rheumatoid arthritis patients and the general population | Q38459919 | ||
| Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States | Q39920404 | ||
| Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate | Q40111750 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 9-18 | |
| P577 | publication date | 2013-12-10 | |
| P1433 | published in | Expert Review of Pharmacoeconomics & Outcomes Research | Q15734522 |
| P1476 | title | Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis | |
| P478 | volume | 14 |
Search more.